| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 47.144 | 43.092 | 2.799 | 1.910 | 2.800 | 4.481 | 3.363 | 2.714 |
| Total Income - EUR | - | - | 47.490 | 43.108 | 2.808 | 3.026 | 3.067 | 4.920 | 3.382 | 3.104 |
| Total Expenses - EUR | - | - | 17.976 | 17.521 | 1.563 | 1.709 | 1.882 | 2.527 | 2.079 | 2.706 |
| Gross Profit/Loss - EUR | - | - | 29.514 | 25.587 | 1.245 | 1.317 | 1.185 | 2.393 | 1.303 | 397 |
| Net Profit/Loss - EUR | - | - | 28.638 | 24.294 | 1.161 | 1.235 | 1.094 | 2.257 | 1.143 | 335 |
| Employees | - | - | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Thirteen Labs Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 0 | 0 | 0 | 0 | 35 | 1.061 | 635 | 210 |
| Current Assets | - | - | 31.399 | 24.575 | 25.223 | 26.669 | 26.610 | 1.681 | 3.253 | 3.973 |
| Inventories | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | 73 | 2.090 | 15 | 485 | 69 | 99 | 221 | 233 |
| Cash | - | - | 31.326 | 22.485 | 25.207 | 26.184 | 26.541 | 1.582 | 3.032 | 3.740 |
| Shareholders Funds | - | - | 28.681 | 24.513 | 25.148 | 25.906 | 26.491 | 2.470 | 3.605 | 3.921 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 2.718 | 62 | 74 | 763 | 153 | 272 | 282 | 262 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6201 - 6201" | |||||||||
| CAEN Financial Year |
6201
|
|||||||||
Comments - Thirteen Labs Srl